Clinical trials: Psychological Disorder
- Condition Psychological Disorder
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Schizophrenia, Bipolar Disorder
Olanzapine Treated Adolescents With Schizophrenia or Bipolar I Disorder
The purpose of this study is to characterize olanzapine pharmacokinetics: the inter- and intra- subject variabilities of olanzapine pharmacokinetics; and the potential influence of patient factors such as age, weight, gender…
- Trial name
- NCT00113594
- Testing
- Olanzapine
- Where
- 17 sites in United States, Puerto Rico and 1 more
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company
GAINS Expert Guiding Technology to Coach Life Skill Teaching
GAINS Expert Guiding Technology to Coach Life Skill Teaching
Based on proven techniques in operant conditioning, the expert behavior guiding functionality in GAINS to teach life skills will be evaluated.
- Trial name
- NCT07203105
- Testing
- GAINS expert guiding technology to coach life skill teaching
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Guiding Technologies Corporation
Alzheimer Disease, Dementia
Assistive Technology and Reduced Caregiver Burden
The study investigated a six-week randomized controlled trial study in a small cohort of 16 family caregivers of individuals living with Alzheimer's disease and related dementias.
- Conditions
- Alzheimer Disease, Dementia, Caregiver Burden, Quality of Life
- Trial name
- ck (NCT05352529)
- Testing
- The MapHabit system, Dementia educational videos
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- MapHabit, Inc.
Autism Spectrum Disorder
Cognoa Autism Spectrum Disorder (ASD) Digital Therapeutic Engagement and Usability Study
Cognoa will measure usability, engagement with the device, and changes in parent-reported socialization during a 4-week period of intervention at home with the Cognoa ASD therapeutic device.
- Trial name
- NCT04326231
- Testing
- Usability assessment of Cognoa ASD Therapeutic Device
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Cognoa, Inc.
ADHD, Predominantly Inattentive Type
Safety and Tolerability Study of Metadoxine Extended Release (MDX) (Previously Known as MG01CI) in PI-ADHD Adolescent Subjects
The purpose of this study is to evaluate the safety and tolerability of a single administration of Metadoxine Extended Release (MDX) formulation for the treatment of adolescents diagnosed with ADHD that have predominantly…
- Trial name
- NCT02189772
- Testing
- Metadoxine extended release
- Where
- 6 sites in Israel
- Volunteers
- 83 people
- Sponsor
- Alcobra Ltd.
Attention-deficit Hyperactivity Disorder
A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine Capsules in Pediatric Subjects With Attention-deficit Hyperactivity Disorder
This is a phase 1b, multicenter, open-label, multiple-dose trial in pediatric subjects (4 - 12 years of age, inclusive) with a confirmed diagnosis of ADHD.
- Trial name
- NCT04786730
- Testing
- Centanafadine
- Where
- 5 sites in United States
- Volunteers
- 50 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Attention Deficit Hyperactivity Disorder
Efficacy and Safety of Atomoxetine in Children With Recent Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD)
Double blinded clinical trial placebo controlled in 153 children (planned enrollment) with recent diagnosis of ADHD. Patients will be randomized to atomoxetine or placebo arm (2:1).
- Trial name
- NCT00191945
- Testing
- Atomoxetine Hydrochloride
- Where
- 11 sites in Spain
- Volunteers
- 151 people
- Sponsor
- Eli Lilly and Company
Chronic Troublesome Sialorrhea, Cerebral Palsy
Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability
The objective of this study is to investigate the efficacy and safety of NT 201 compared with placebo for the treatment of chronic troublesome sialorrhea associated with neurological disorders (e.g.
- Conditions
- Chronic Troublesome Sialorrhea, Cerebral Palsy, Stroke, Traumatic Brain Injury
- Trial name
- SIPEXI (NCT02270736)
- Testing
- NT 201
- Where
- 31 sites in Georgia, Hungary and 4 more
- Volunteers
- 256 people
- Sponsor
- Merz Pharmaceuticals GmbH
ADHD
PRC-063 in Adolescent ADHD
The purpose of this randomized, placebo-controlled, double-blind, parallel group study is to evaluate the clinical efficacy and safety of PRC-063 in adolescents with ADHD.
- Trial name
- NCT02139111
- Testing
- PRC-063 25 mg, PRC-063 45 mg, PRC-063 70 mg
- Where
- 43 sites in United States, Canada
- Volunteers
- 360 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
ADHD
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD
This study will evaluate the efficacy and safety of low doses of SPN-812 in adolescents 12-17 years of age.
- Trial name
- NCT03247517
- Testing
- 200mg SPN-812, 400mg SPN-812
- Where
- 12 sites in United States
- Volunteers
- 310 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Down Syndrome, Cognitive Dysfunction
Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10
The purpose of this study is to determine the efficacy and safety of donepezil hydrochloride (Aricept) in the treatment of cognitive dysfunction shown by children with Down syndrome, aged 6 to 10 years.
- Trial name
- NCT00754013
- Testing
- Aricept (Donepezil hydrochloride)
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Eisai Inc.
Attention Deficit Disorder With Hyperactivity
Compliance Survey of ADHD Medication for Optimal Satisfaction (COSMOS)
The survey is designed to identify non-compliant Attention Deficit Hyperactivity Disorder (ADHD) patients who are currently on Immediate- Released Methylphenidate (IR-MPH) and observe any change in compliance after treating with…
- Trial name
- NCT00460720
- Testing
- Observational treatment compliance survey
- Volunteers
- 591 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Attention Deficit-Hyperactivity Disorder
Effectiveness of a Personalized Neurofeedback Training Device (ADHD@Home) in Attention-Deficit/Hyperactivity Disorder
The main objective of the study is to demonstrate the non-inferiority of the personalized Neurofeedback Training device versus Methylphenidate in the treatment of children and adolescents with Attention-Deficit/Hyperactivity…
- Trial name
- Newrofeed (NCT02778360)
- Testing
- Neurofeedback NFT, Methylphenidate MPH
- Where
- 12 sites in Belgium, France and 3 more
- Volunteers
- 179 people
- Sponsor
- Mensia Technologies SA
Restless Legs Syndrome
Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)
The objectives of this Post Marketing Surveillance (PMS) are: Evaluation of the treatment effect of pramipexole on Restless Legs Syndrome (RLS) severity as measured by International Restless Legs Syndrome Scale (IRLS) and…
- Trial name
- NCT02248155
- Testing
- Pramipexole
- Volunteers
- 2,644 people
- Sponsor
- Boehringer Ingelheim
Alzheimer's Disease
Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients
This study will assess the safety, tolerability and Abeta-specific antibody response of repeated intra-muscular injections of adjuvanted CAD106 in patients with mild Alzheimer's Disease.
- Trial name
- NCT01097096
- Testing
- CAD106, Alum, MF59
- Where
- 31 sites in United States, Belgium and 8 more
- Volunteers
- 177 people
- Sponsor
- Novartis Pharmaceuticals
ADHD
Efficacy and Safety of SPD503 in Combination With Psychostimulants
The purpose of this study is to assess the efficacy and safety of SPD503 in subjects with ADHD when co-administered with psychostimulants in children and adolescents aged 6-17 years with a diagnosis of ADHD with a sub-optimal…
- Trial name
- NCT00734578
- Testing
- SPD503-AM, SPD503-PM
- Where
- 61 sites in United States
- Volunteers
- 461 people
- Sponsor
- Shire
Autism Spectrum Disorder (ASD)
TeleABA for Hospitalized Adolescents and Young Adults With Autism Spectrum Disorder
This study is evaluating whether a telehealth-based applied behavior analysis (ABA) program can improve the care of adolescents and young adults with autism spectrum disorder (ASD) who are hospitalized because of severe…
- Trial name
- NCT07701915
- Testing
- Standard Hospital Care, Telehealth Applied Behavior Analysis (TeleABA)
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- Caring Technologies, Inc.
Autism, Autistic Disorder
An Open-Label Study to Evaluate the Efficacy of High-Dose Gammaplex in Children on the Autism Spectrum
If autism is the consequence of a chronic inflammatory process preventing the infant brain from forming the proper neural connections, then treatment that reduces inflammation might have a positive impact on autism.
- Conditions
- Autism, Autistic Disorder, Asperger's Disorder, PDD
- Trial name
- NCT02199925
- Testing
- Gammaplex 5%
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Isaac Melamed
Epilepsy, Bipolar Disorder
Lamotrigine Pregnancy Registry (LAM05)
Antiepileptic drugs (AEDs) are not indicated for use in pregnancy. However, women with epilepsy, and other approved indications including bipolar disorder, may require or be unintentionally exposed to AEDs during pregnancy.
- Trial name
- NCT01064297
- Testing
- Lamotrigine monotherapy, Lamotrigine polytherapy including valproate, Lamotrigine polytherapy without valproate
- Volunteers
- 3,416 people
- Sponsor
- GlaxoSmithKline
Velo-cardio-facial Syndrome, Psychosis
Metyrosine (Demser®) for the Treatment of Psychotic Disorders in Patients With Velocardiofacial Syndrome
This is an exploratory clinical investigation. The objectives of this study are to evaluate the safety, steady-state pharmacokinetics, and efficacy of metyrosine (Demser®) for the treatment of psychosis in patients with…
- Trial name
- NCT01127503
- Testing
- Metyrosine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Bausch Health Americas, Inc.